Literature DB >> 12018625

Renal ultrastructural findings in Anderson-Fabry disease.

Adalberto Sessa1, Antonella Toson, Manuela Nebuloni, Francesco Pallotti, Ferdinando Giordano, Graziana Battini, Alessia Maglio, Mietta Meroni, Gilberto Calconi, Gabriele Bertolone, Pierlucio Gatti.   

Abstract

Anderson-Fabry disease (AFd) is caused by an X-linked inborn error in the glycosphingoLipid metabolic pathway due to an enzymatic defect in a lysosomal hydrolase: alpha-galactosidase A. The defect results in the progressive accumulation of neutral glycosphingolipids in most body fluids and several tissues. The clinical manifestations of AFd are related to organ damage and, obviously, are more severe in hemizygous males than in heterozygous females. In the third decade of life, the course of the disease involves severe deterioration of kidney function progressing to end-stage renal failure. All kind of cells of renal structures are filled with glycosphingolipid deposits. Electron microscopic studies document typical intracytoplasmic osmiophilic bodies with a characteristic "zebra" or "onion-skin" appearance due to concentric lamellation of alternating clear and dark layers. Clinical interest in Fabry patients is related to recent advances in treatment with an intravenous specific enzyme to modify the biochemical error of the glycosphingolipid catabolic pathway.

Entities:  

Mesh:

Year:  2002        PMID: 12018625

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  10 in total

1.  Immunohistochemical diagnosis of Fabry nephropathy and localisation of globotriaosylceramide deposits in paraffin-embedded kidney tissue sections.

Authors:  Carmen Valbuena; Dina Leitão; Fátima Carneiro; João Paulo Oliveira
Journal:  Virchows Arch       Date:  2011-12-29       Impact factor: 4.064

2.  Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease.

Authors:  M Ries; H J Kim; C K Zalewski; M A Mastroianni; D F Moore; R O Brady; J M Dambrosia; R Schiffmann; C C Brewer
Journal:  Brain       Date:  2006-11-14       Impact factor: 13.501

3.  Kidney histologic alterations in α-Galactosidase-deficient mice.

Authors:  Carmen Valbuena; João Paulo Oliveira; Fátima Carneiro; Sandra Relvas; Mariana Ganhão; M Clara Sá-Miranda; Lorena G Rodrigues
Journal:  Virchows Arch       Date:  2011-02-16       Impact factor: 4.064

4.  Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN).

Authors:  Agnes B Fogo; Leif Bostad; Einar Svarstad; William J Cook; Solange Moll; Federic Barbey; Laurette Geldenhuys; Michael West; Dusan Ferluga; Bojan Vujkovac; Alexander J Howie; Aine Burns; Roy Reeve; Stephen Waldek; Laure-Hélène Noël; Jean-Pierre Grünfeld; Carmen Valbuena; João Paulo Oliveira; Justus Müller; Frank Breunig; Xiao Zhang; David G Warnock
Journal:  Nephrol Dial Transplant       Date:  2009-10-15       Impact factor: 5.992

5.  Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy.

Authors:  Carmen Valbuena; Elísio Carvalho; Manuela Bustorff; Mariana Ganhão; Sandra Relvas; Rosete Nogueira; Fátima Carneiro; João Paulo Oliveira
Journal:  Virchows Arch       Date:  2008-09-04       Impact factor: 4.064

Review 6.  Unusual renal presentation of Fabry disease in a female patient.

Authors:  Cataldo Abaterusso; Vincenzo De Biase; Alessandro Salviati; Antonia Fabris; Deborah Millardi; Paola Tomei; Patrizia Bernich; Antonio Lupo; Giovanni Gambaro
Journal:  Nat Rev Nephrol       Date:  2009-04-28       Impact factor: 28.314

Review 7.  Fabry disease in the era of enzyme replacement therapy: a renal perspective.

Authors:  Monique E Cho; Jeffrey B Kopp
Journal:  Pediatr Nephrol       Date:  2004-04-03       Impact factor: 3.714

8.  Clinical significance of plasma globotriaosylsphingosine levels in Chinese patients with Fabry disease.

Authors:  Yan Ouyang; Bing Chen; Xiaoxia Pan; Zhaohui Wang; Hong Ren; Yaowen Xu; Liyan Ni; Xialian Yu; Li Yang; Nan Chen
Journal:  Exp Ther Med       Date:  2018-02-26       Impact factor: 2.447

9.  Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease.

Authors:  Fernando C Fervenza; Roser Torra; David G Warnock
Journal:  Biologics       Date:  2008-12

Review 10.  Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?

Authors:  Stephen Waldek; Sandro Feriozzi
Journal:  BMC Nephrol       Date:  2014-05-06       Impact factor: 2.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.